VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine

Vaccine Information

Vaccine Name: Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007320
Type: Recombinant vector vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
SPA17 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
ROPN1 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
AKAP4 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
PTTG1 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
SPANXB1 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
Preparation: DC are pulsed with tumor-associated antigen (Mastelic-Gavillet et al., 2019).
Description: A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with specific tumor-associated peptide antigens (TAPA), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous TAPA-pulsed DC vaccine exposes the immune system to the specific TAPAs, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the TAPA-expressing cancer cells. This leads to cancer cell lysis. This vaccine is specific towards peptides derived from the following proteins: sperm autoantigenic protein 17 (SP17), ropporin, A-kinase anchor protein 4 (AKAP4), pituitary tumor-transforming 1 (PTTG1) and SPANX family member B (SPANX-B). (NCIT_C126797).

This vaccine has been used in clinical trials involving melanoma and ovarian cancer. (Redman et al., 2008; Kandalaft et al., 2013)

Host Response

References

Kandalaft et al., 2013: Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2013; 2(1); e22664. [PubMed: 23482679].

Mastelic-Gavillet et al., 2019: Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Frontiers in immunology. 2019; 10; 766. [PubMed: 31031762].

NCIT_C126797: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C126797]

Redman et al., 2008: Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(6); 591-598. [PubMed: 18528294].